Cargando…

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Michael, Smyth, Elizabeth C, Cunningham, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966750/ https://www.ncbi.nlm.nih.gov/pubmed/27524910 http://dx.doi.org/10.2147/OTT.S84153

Ejemplares similares

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
por: Li, Sini, et al.
Publicado: (2020)

Spontaneous Regression of Metastatic Lesions of Adenocarcinoma of the Gastro-Esophageal Junction
por: Mitchell, Richard, et al.
Publicado: (2021)

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma(†)
por: Al-Batran, S.-E., et al.
Publicado: (2016)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data
por: Muro, Kei, et al.
Publicado: (2019)

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab
por: Ruzzo, Annamaria, et al.
Publicado: (2020)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
por: Rakusic, Zoran, et al.
Publicado: (2020)

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
por: Gullo, Irene, et al.
Publicado: (2015)

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
por: Han, Hye Sook, et al.
Publicado: (2021)

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas
por: Reim, Daniel, et al.
Publicado: (2020)

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
por: Li, Yuhong, et al.
Publicado: (2015)

Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer
por: Morelli, Cristina, et al.
Publicado: (2022)

Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting
por: Sanjeevaiah, Aravind, et al.
Publicado: (2020)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel
por: Matsubara, Yuki, et al.
Publicado: (2017)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
por: Propper, David, et al.
Publicado: (2016)

Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference
por: Mulder, Karen, et al.
Publicado: (2022)

Adenocarcinoma of oesophagus involving gastro-oesophageal junction following mini-gastric bypass/ one anastomosis gastric bypass
por: Aggarwal, Sandeep, et al.
Publicado: (2020)

Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials
por: Swed, Sarya, et al.
Publicado: (2022)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
por: Yang, Hongqiong, et al.
Publicado: (2021)

Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Kim, Hyung-Don, et al.
Publicado: (2020)

Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report
por: Yang, Min Joo, et al.
Publicado: (2021)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
por: Pinto, C, et al.
Publicado: (2009)

Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
por: Dahle-Smith, Åsa, et al.
Publicado: (2015)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
por: Shah, Manish A., et al.
Publicado: (2022)

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
por: Lorenzen, Sylvie, et al.
Publicado: (2023)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014)

The Prognostic Impact of Histology in Esophageal and Esophago-Gastric Junction Adenocarcinoma
por: Fiocca, Roberto, et al.
Publicado: (2021)

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
por: Zeng, Hanqing, et al.
Publicado: (2022)

A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma
por: Mirza, A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qt03i5opkantpr1t9s3ufvs6pl